Tag Archives: ProNAi Therapeutics

Cdc7 inhibitor for the treatment of cancer

ProNai Therapeutics is a Canadian biotech company that recently licensed the rights to a small molecule inhibitor of Cdc7 (cell division cycle 7), a key regulator of both DNA replication and DNA damage response. The drug has shown activity against several cancers in preclinical studies. Continue reading